Research programme: antibacterial antibodies - Sorrento Therapeutics

Drug Profile

Research programme: antibacterial antibodies - Sorrento Therapeutics

Alternative Names: Anti-AIP mAbs; Anti-API1 mAb; Anti-API2 mAbs; Anti-MRSA antibodies - Sorrento Therapeutics; STI 001 program - Sorrento; STI-C0205; STI-C020X

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Sorrento Therapeutics
  • Developer Montana State University; Ohio State University; Sorrento Therapeutics
  • Class Antibodies; Bispecific antibodies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants; Peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
  • No development reported Clostridium infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Clostridium-infections in USA (Parenteral)
  • 01 Jul 2014 Sorrento Therapeutics receives two STTR grants from National Institute of Allergy and Infectious Diseases for development of antibody therapeutics in Staphylococcus aureus infections and Pseudomonal infections
  • 01 Jul 2014 Preclinical trials in Pseudomonal infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top